Overdose deaths have inflicted a terrible toll on American families and communities. For years, the trend line seemed relentlessly grim. That is beginning to change.
Overdose fatalities fell 26.2% from 2023 to 2024, and the latest provisional data from the Centers for Disease Control and Prevention (CDC) predicts 67,798 drug overdose deaths over the last 12 months ending in March 2026 which is a 12.3% decline from the same period a year earlier.
Those numbers do not mean the crisis is over. Tens of thousands of Americans are still dying from drug overdoses. But the direction has changed, and that progress warrants attention.
The Trump Administration’s approach is centered on three connected priorities: preventing fatal overdoses, addressing the evolving threats that drive them, and ensuring that people with substance-use disorders can access evidence-based treatment and long-term recovery support. Policymakers should take note of this strategy, as it is contributing to the positive progress we are seeing in overdose trends.
First, effective overdose-reversal medications remain essential. Access to naloxone has expanded as the medication has become increasingly available through pharmacies, community organizations, schools and emergency-response systems. In March 2023, the Food and Drug Administration (FDA) approved the first over-the-counter naloxone nasal spray, making it easier for families and individuals to keep this lifesaving medication on hand. In June 2026, the Trump administration’s FDA approved another over-the-counter naloxone nasal spray for the emergency treatment of opioid overdose. These approvals contribute to the broader goal of ensuring that proven overdose-reversal tools are available when opioid exposure becomes life threatening.
That matters because overdose is not synonymous with addiction. Some people who overdose are struggling with addiction and need treatment and long-term support. Others may have used an illicit drug only occasionally, may have been experimenting, or may have unknowingly consumed a substance containing fentanyl. A single, dangerous exposure of illicit fentanyl can be fatal even when a person does not have a substance use disorder.
Public policy should recognize both realities. In the event of an overdose, the immediate priority is saving the person's life. What comes next should depend on a person’s needs. For someone with a substance-use disorder, surviving that crisis can create an opportunity to connect to evidence-based treatment and recovery services.
Second, evidence-based treatment can address the underlying condition when addiction is present. Medications such as buprenorphine, methadone and naltrexone are important components used in treatment, alongside counseling, peer support, behavioral therapy and other forms of recovery. But medication should be part of a comprehensive, individualized approach that also addresses a person’s behavioral, physical and social needs through counseling, peer support and other treatment and recovery services.
Third, prevention policy must keep pace with a rapidly changing illicit drug market. Illicit fentanyl transformed the illicit drug market and dramatically increased the lethality of opioid exposure. CDC data shows that the overdose death rate involving synthetic opioids other than methadone fell substantially from 2023 to 2024, but the drug supply remains unpredictable and new synthetic substances continue to emerge. Prevention also means giving patients and clinicians more options to manage pain. Expanding access to effective non-opioid approaches can provide additional choices for treating acute and chronic pain while reducing unnecessary exposure to opioids.
The Trump Administration has also sought to disrupt the financial and chemical networks behind illicit fentanyl. The U.S. Department of the Treasury has used sanctions and other authorities to target financial institutions, companies and trafficking networks connected to illicit fentanyl production and the procurement of precursor chemicals. Treasury has also taken action against Chinese chemical companies and other networks involved in supplying materials used in the production of illicit fentanyl.
These enforcement actions are part of a broader effort to reduce the supply of illicit fentanyl. It is difficult to assign the recent decline in overdose deaths to any single enforcement measure. But disrupting the financial and chemical infrastructure behind illicit fentanyl is an important part of reducing the threat.
The Trump Administration and the U.S. Department of Health and Human Services (HHS) are also building on significant federal investments across the continuum of care.
The Administration has continuously emphasized partnerships among states, local communities, tribes, territories, and treatment professionals as part of its broader recovery strategy. In 2025, the Substance Abuse and Mental Health Services Administration (SAMHSA) under HHS awarded approximately $1.5 billion through State Opioid Response grants and $63 million through Tribal Opioid Response grants to support prevention, treatment, overdose reversal, and recovery. In 2026, SAMHSA also awarded $69.4 million to expand access to medications for opioid use disorder, $34.6 million to strengthen first responder overdose response, and approximately $11 million for community-based overdose prevention.
That holistic approach extends beyond addressing crises to also addressing the underlying conditions that perpetuate them. Rather than treating housing as an endpoint, HHS and the U.S. Department of Housing and Urban Development are emphasizing housing alongside evidence-based services that can help people address substance-use disorders and move toward long-term stability.
For policymakers, these investments illustrate an important principle: overdose policy should be judged not only by whether it keeps someone alive in a moment of crisis, but by whether the broader system can connect that person to effective treatment and support a sustained return to recovery, work and stability.
President Trump’s nomination of Dr. Timothy Westlake, M.D., FACEP, to lead SAMHSA is another positive signal. Dr. Westlake brings more than 25 years of experience as an emergency physician, along with extensive work shaping state and federal policy to confront the opioid and fentanyl crisis. If confirmed, his combination of frontline clinical experience and policy expertise can help SAMHSA build on the progress we are seeing and keep the agency focused on what matters most: helping Americans struggling with mental illness or substance-use disorders access effective treatment, achieve lasting recovery and rebuild healthy, meaningful lives.
Dr. Westlake was favorably reported out of the Senate Committee on Health, Education, Labor, and Pensions on September 30, 2026, and should be confirmed by the full U.S. Senate before the end of the year. His nomination comes at an important time as HHS and the Trump Administration work to meet the moment.
The decline in overdose deaths is encouraging, but it is not a reason for complacency. It should be an opportunity to examine what is working, strengthen effective interventions, and keep improving the systems that move people from crisis to treatment and from treatment to sustained recovery.
The Trump Administration has made meaningful progress during the past eighteen months, but the crisis is far from over. Saving a life from an overdose is an essential first step, but what comes next depends on the individual. For someone struggling with addiction, it should be a pathway to treatment and lasting recovery. Yet, for someone exposed unknowingly to fentanyl or another dangerous substance, it may mean ensuring that a single exposure does not become a fatal one.
A comprehensive response must recognize both realities. Sustaining the progress we are seeing will require continued focus on what works, adapting to emerging threats, and never losing sight of the lives we are working to save.
Dr. Andres is Assistant Secretary for Legislation at the U.S. Department of Health and Human Services (HHS). Ms. Bretan is the Director of Congressional Liaison in the Office of the Assistant Secretary for Legislation at HHS.
